Scarica l'app Stockscreener
2.45
7.46%
0.17
Pre-mercato:
2.40
-0.05
-2.04%
Precedente Chiudi:
$2.28
Aprire:
$2.2
Volume 24 ore:
173.35K
Relative Volume:
0.41
Capitalizzazione di mercato:
$181.87M
Reddito:
-
Utile/perdita netta:
$-2.95M
Rapporto P/E:
-60.95
EPS:
-0.0402
Flusso di cassa netto:
-
1 W Prestazione:
+21.29%
1M Prestazione:
+11.36%
6M Prestazione:
-95.29%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.14
$2.54
Intervallo di 1 settimana:
$1.88
$2.54
Portata 52W:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare MENS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.45 | 181.87M | 0 | -2.95M | 0 | -0.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - stocktitan.net
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - stocktitan.net
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - stocktitan.net
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - stocktitan.net
Jyong Biotech (MENS) director files Form 3 with no insider trades - stocktitan.net
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
A plant-based prostate drug finished Phase III trials in the U.S. and Taiwan - stocktitan.net
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - The Manila Times
MENS Technical Analysis & Stock Price Forecast - Intellectia AI
Prostate cancer therapy also lowers cholesterol in 2-year trial - stocktitan.net
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer By Investing.com - Investing.com India
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer - Investing.com Nigeria
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer - TipRanks
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
Jyong Biotech subsidiary announces phase II data for MCS-8 - TipRanks
Jyong Biotech reports positive results from MCS-8 phase II trial - Investing.com
Prostate cancer trial drug also improves cholesterol in 2-year study - stocktitan.net
Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results - TipRanks
Jyong Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
FLYEXCLUSIVE INC. (FLYX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):